NO20043695L - Selektive dipeptidinhibitorer av kallikrein - Google Patents

Selektive dipeptidinhibitorer av kallikrein

Info

Publication number
NO20043695L
NO20043695L NO20043695A NO20043695A NO20043695L NO 20043695 L NO20043695 L NO 20043695L NO 20043695 A NO20043695 A NO 20043695A NO 20043695 A NO20043695 A NO 20043695A NO 20043695 L NO20043695 L NO 20043695L
Authority
NO
Norway
Prior art keywords
kallikrein
dipeptide inhibitors
selective dipeptide
selective
inhibitors
Prior art date
Application number
NO20043695A
Other languages
English (en)
Other versions
NO332678B1 (no
Inventor
David Michael Evans
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of NO20043695L publication Critical patent/NO20043695L/no
Publication of NO332678B1 publication Critical patent/NO332678B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20043695A 2002-03-08 2004-09-03 Selektive dipeptidinhibitorer av kallikrein NO332678B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205527.5A GB0205527D0 (en) 2002-03-08 2002-03-08 Inhibitors
PCT/GB2003/000908 WO2003076458A2 (en) 2002-03-08 2003-03-04 Selective dipeptide inhibitors of kallikrein

Publications (2)

Publication Number Publication Date
NO20043695L true NO20043695L (no) 2004-10-07
NO332678B1 NO332678B1 (no) 2012-12-03

Family

ID=9932619

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043695A NO332678B1 (no) 2002-03-08 2004-09-03 Selektive dipeptidinhibitorer av kallikrein

Country Status (26)

Country Link
US (1) US7649000B2 (no)
EP (1) EP1483284B1 (no)
JP (1) JP4330450B2 (no)
KR (1) KR100974633B1 (no)
CN (1) CN1274713C (no)
AR (1) AR039868A1 (no)
AT (1) ATE333463T1 (no)
AU (1) AU2003208471B2 (no)
CA (1) CA2478099C (no)
DE (1) DE60306904T2 (no)
DK (1) DK1483284T3 (no)
EG (1) EG25482A (no)
ES (1) ES2264523T3 (no)
GB (1) GB0205527D0 (no)
IL (2) IL163710A0 (no)
MX (1) MXPA04008523A (no)
MY (1) MY130830A (no)
NO (1) NO332678B1 (no)
NZ (1) NZ534891A (no)
PL (1) PL209670B1 (no)
PT (1) PT1483284E (no)
RU (1) RU2301225C2 (no)
TW (1) TWI283685B (no)
UY (1) UY27699A1 (no)
WO (1) WO2003076458A2 (no)
ZA (1) ZA200406856B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
GB0918924D0 (en) * 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB2517908A (en) * 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
WO2015063465A2 (en) * 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
ME03794B (me) 2016-05-31 2021-04-20 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CA3117549A1 (en) 2018-10-30 2020-05-07 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
WO2022084693A1 (en) 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
EP4673437A1 (en) 2023-02-27 2026-01-07 Kalvista Pharmaceuticals Limited New solid form of a plasma kallikrein inhibitor
WO2025153806A1 (en) 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
AU2882792A (en) * 1991-10-23 1993-05-21 Procter & Gamble Company, The Tripeptide derivative anti-inflammatory agents
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors

Also Published As

Publication number Publication date
PT1483284E (pt) 2006-11-30
IL163710A (en) 2010-12-30
MY130830A (en) 2007-07-31
PL372977A1 (en) 2005-08-08
KR20040089705A (ko) 2004-10-21
CN1639186A (zh) 2005-07-13
US7649000B2 (en) 2010-01-19
JP2005533750A (ja) 2005-11-10
GB0205527D0 (en) 2002-04-24
CN1274713C (zh) 2006-09-13
UY27699A1 (es) 2003-10-31
MXPA04008523A (es) 2004-12-06
DE60306904D1 (de) 2006-08-31
TWI283685B (en) 2007-07-11
JP4330450B2 (ja) 2009-09-16
AU2003208471A1 (en) 2003-09-22
NO332678B1 (no) 2012-12-03
WO2003076458A3 (en) 2003-11-06
NZ534891A (en) 2006-03-31
RU2301225C2 (ru) 2007-06-20
CA2478099C (en) 2011-10-04
ZA200406856B (en) 2005-11-30
EP1483284B1 (en) 2006-07-19
CA2478099A1 (en) 2003-09-18
PL209670B1 (pl) 2011-10-31
DE60306904T2 (de) 2007-02-08
EG25482A (en) 2012-01-15
ES2264523T3 (es) 2007-01-01
ATE333463T1 (de) 2006-08-15
TW200403255A (en) 2004-03-01
US20060052313A1 (en) 2006-03-09
WO2003076458A2 (en) 2003-09-18
KR100974633B1 (ko) 2010-08-06
AR039868A1 (es) 2005-03-09
IL163710A0 (en) 2005-12-18
HK1072265A1 (en) 2005-08-19
EP1483284A2 (en) 2004-12-08
RU2004126610A (ru) 2005-05-27
DK1483284T3 (da) 2006-10-16
AU2003208471B2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DK1483284T3 (da) Selektive dipeptidinhibitorer af kallikrein
NO20043645L (no) Sykloalkylinhibitorer av kaliumkanal-funksjon
EP1499336A4 (en) PROTEASE INHIBITORS
DK1699455T3 (da) Heterocykliske aspartylproteasehæmmere
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
LU93072I2 (fr) Inhibiteur de la protéinase alpha-1 humaine
DE60319430D1 (de) R- und fgfr-inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
EP1549316A4 (en) HAMMER OF TFGbeta
EP1474093A4 (en) Granzyme B INHIBITORS
DK1501508T3 (da) Inhibitorer af histondeatylase
EP1467951A4 (en) ACTIVE ACOUSTIC PIPING
NO20034308L (no) Nye tyrokinase-inhibitorer
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
DE602004018837D1 (de) Ptidase-iv-inhibitoren
NO20016034L (no) Inhibitorer av aspartylprotease
EP1660436A4 (en) cathepsin inhibitors
NO20052348D0 (no) Behandling av hemoragisk sjokk
NO20050118D0 (no) Substituerte fenylsulfonamidinhibitorer av beta-amyolid produksjon
NO20044916L (no) Preparater av sulfinylacetamid
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
NO20050563L (no) N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees